published meta-analysis   sensitivity analysis   studies

colchicine in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsCOL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] 0.24[0.01; 5.41]COL-COVID (Pascual-Figal), 202110%103NAnot evaluable deathsdetailed resultsCOL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] Lopes MIF, 2020 1.06 [0.02; 56.61] 0.42[0.04; 4.91]COL-COVID (Pascual-Figal), 2021, Lopes MIF, 202020%138moderatenot evaluable clinical deteriorationdetailed resultsCOL-COVID (Pascual-Figal), 2021 0.38 [0.09; 1.58] 0.38[0.09; 1.58]COL-COVID (Pascual-Figal), 202110%103NAnot evaluable mechanical ventilationdetailed resultsCOL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] 0.24[0.01; 5.41]COL-COVID (Pascual-Figal), 202110%103NAnot evaluable ICU admissiondetailed resultsCOL-COVID (Pascual-Figal), 2021 0.47 [0.08; 2.69] 0.47[0.08; 2.69]COL-COVID (Pascual-Figal), 202110%103NAnot evaluable serious adverse eventsdetailed resultsCOL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] 0.24[0.01; 5.41]COL-COVID (Pascual-Figal), 202110%103NAnot evaluable adverse eventsdetailed resultsCOL-COVID (Pascual-Figal), 2021 1.72 [0.73; 4.08] 1.72[0.73; 4.08]COL-COVID (Pascual-Figal), 202110%103NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-03-28 15:28 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 560,1102 - roots T: 290